Ochre Bio, a pioneer in chronic liver disease medicine development, has announced the start of a multi-year data license agreement with GSK. The partnership will provide GSK with access to Ochre Bio’s computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive access to their extensive library of historical liver data. The collaboration will enable Ochre Bio and GSK to deepen the understanding of liver biology, aligned with GSK’s disease area focus in hepatology, with the aim to further prioritize and accelerate development of medicines to address liver disease. The data will be used by both Ochre Bio and GSK to build better AI models, allowing for fewer, but more precise experiments to aid in target choice.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK starts process for appeal of recent Delaware Daubert ruling
- GSK ‘welcomes’ plaintiff’s voluntary dismissal of Kasza Zantac case
- GSK reports FDA approves expanded age indication for AREXVY
- GSK acquired Elsie Biotechnologies for up to $50M
- Jefferies says global Zantac settlement unlikely until Delaware hears GSK appeal